Search Results - "Boccadoro, M."

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Dimopoulos, M.A., Moreau, P., Terpos, E., Mateos, M.V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., Goldschmidt, H., Facon, T., Einsele, H., Boccadoro, M., San-Miguel, J., Sonneveld, P., Mey, U.

“…•This EHA-ESMO Clinical Practice Guideline provides key recommendations on the management of multiple myeloma.•Authorship includes a multidisciplinary group of…”
Get full text

Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders by Ladetto, M, Brüggemann, M, Monitillo, L, Ferrero, S, Pepin, F, Drandi, D, Barbero, D, Palumbo, A, Passera, R, Boccadoro, M, Ritgen, M, Gökbuget, N, Zheng, J, Carlton, V, Trautmann, H, Faham, M, Pott, C

“…In this study, we compared immunoglobulin heavy-chain-gene-based minimal residual disease (MRD) detection by real-time quantitative PCR (RQ-PCR) and…”
Get full text

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management by Kyle, R A, Durie, B G M, Rajkumar, S V, Landgren, O, Blade, J, Merlini, G, Kröger, N, Einsele, H, Vesole, D H, Dimopoulos, M, San Miguel, J, Avet-Loiseau, H, Hajek, R, Chen, W M, Anderson, K C, Ludwig, H, Sonneveld, P, Pavlovsky, S, Palumbo, A, Richardson, P G, Barlogie, B, Greipp, P, Vescio, R, Turesson, I, Westin, J, Boccadoro, M

“…Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older…”
Get full text

Autologous Transplantation and Maintenance Therapy in Multiple Myeloma by Palumbo, Antonio, Cavallo, Federica, Gay, Francesca, Di Raimondo, Francesco, Ben Yehuda, Dina, Petrucci, Maria Teresa, Pezzatti, Sara, Caravita, Tommaso, Cerrato, Chiara, Ribakovsky, Elena, Genuardi, Mariella, Cafro, Anna, Marcatti, Magda, Catalano, Lucio, Offidani, Massimo, Carella, Angelo Michele, Zamagni, Elena, Patriarca, Francesca, Musto, Pellegrino, Evangelista, Andrea, Ciccone, Giovannino, Omedé, Paola, Crippa, Claudia, Corradini, Paolo, Nagler, Arnon, Boccadoro, Mario, Cavo, Michele

“…In patients 65 or younger with multiple myeloma, high-dose consolidation therapy was associated with longer survival and more myelotoxicity than…”
Get full text

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network by Terpos, E., Sezer, O., Croucher, P.I., García-Sanz, R., Boccadoro, M., San Miguel, J., Ashcroft, J., Bladé, J., Cavo, M., Delforge, M., Dimopoulos, M.-A., Facon, T., Macro, M., Waage, A., Sonneveld, P.

“…Bisphosphonates (BPs) prevent, reduce, and delay multiple myeloma (MM)-related skeletal complications. Intravenous pamidronate and zoledronic acid, and oral…”
Get full text

Second-generation Proteasome Inhibition: What a Difference a Generation Makes by Boccadoro, M

Get full text

Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension by Bringhen, S., Milan, A., D'Agostino, M., Ferri, C., Wäsch, R., Gay, F., Larocca, A., Offidani, M., Zweegman, S., Terpos, E., Goldschmidt, H., Cavo, M., Ludwig, H., Driessen, C., Auner, H. W., Caers, J., Gramatzki, M., Dimopoulos, M. A., Boccadoro, M., Einsele, H., Sonneveld, P., Engelhardt, M.

“…Background The novel proteasome inhibitor carfilzomib alone or in combination with other agents is already one of the standard therapies for relapsed and/or…”
Get full text

Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival by Ferrero, S, Ladetto, M, Drandi, D, Cavallo, F, Genuardi, E, Urbano, M, Caltagirone, S, Grasso, M, Rossini, F, Guglielmelli, T, Cangialosi, C, Liberati, A M, Callea, V, Carovita, T, Crippa, C, De Rosa, L, Pisani, F, Falcone, A P, Pregno, P, Oliva, S, Terragna, C, Musto, P, Passera, R, Boccadoro, M, Palumbo, A

“…Polymerase chain reaction (PCR)-based minimal residual disease (MRD) analysis is a useful prognostic tool in multiple myeloma (MM), although its long-term…”
Get full text

Electrode wear protection mechanism in meso–micro-EDM by Maradia, U., Boccadoro, M., Stirnimann, J., Kuster, F., Wegener, K.

“…A carbonaceous layer builds up on the electrode surface in electrical discharge machining (EDM) when using low wear settings. Current paper investigates the…”
Get full text

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders by Dispenzieri, A, Kyle, R, Merlini, G, Miguel, J S, Ludwig, H, Hajek, R, Palumbo, A, Jagannath, S, Blade, J, Lonial, S, Dimopoulos, M, Comenzo, R, Einsele, H, Barlogie, B, Anderson, K, Gertz, M, Harousseau, J L, Attal, M, Tosi, P, Sonneveld, P, Boccadoro, M, Morgan, G, Richardson, P, Sezer, O, Mateos, M V, Cavo, M, Joshua, D, Turesson, I, Chen, W, Shimizu, K, Powles, R, Rajkumar, S V, Durie, B G M

“…The serum immunoglobulin-free light chain (FLC) assay measures levels of free κ and λ immunoglobulin light chains. There are three major indications for the…”
Get full text

Extracellular vesicles as potential biomarkers of acute graft-vs-host disease by Lia, G, Brunello, L, Bruno, S, Carpanetto, A, Omedè, P, Festuccia, M, Tosti, L, Maffini, E, Giaccone, L, Arpinati, M, Ciccone, G, Boccadoro, M, Evangelista, A, Camussi, G, Bruno, B

“…Acute graft-vs-host disease (GVHD) is a serious complication after allografting. We carried out an exploratory study to investigate a potential correlation of…”
Get full text

The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation by Farina, L, Bruno, B, Patriarca, F, Spina, F, Sorasio, R, Morelli, M, Fanin, R, Boccadoro, M, Corradini, P

“…The hematopoietic cell transplantation specific comorbidity index (HCT-CI) has been developed to identify patients at high risk of mortality after an…”
Get full text

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma by Palumbo, A, Rajkumar, S V, Dimopoulos, M A, Richardson, P G, San Miguel, J, Barlogie, B, Harousseau, J, Zonder, J A, Cavo, M, Zangari, M, Attal, M, Belch, A, Knop, S, Joshua, D, Sezer, O, Ludwig, H, Vesole, D, Bladé, J, Kyle, R, Westin, J, Weber, D, Bringhen, S, Niesvizky, R, Waage, A, von Lilienfeld-Toal, M, Lonial, S, Morgan, G J, Orlowski, R Z, Shimizu, K, Anderson, K C, Boccadoro, M, Durie, B G, Sonneveld, P, Hussein, M A

“…The incidence of venous thromboembolism (VTE) is more than 1‰ annually in the general population and increases further in cancer patients. The risk of VTE is…”
Get full text

Corrigendum to “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’” by Dimopoulos, M.A., Moreau, P., Terpos, E., Mateos, M.V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., Goldschmidt, H., Facon, T., Einsele, H., Boccadoro, M., San-Miguel, J., Sonneveld, P., Mey, U.

Get full text

Circulating miRNA markers show promise as new prognosticators for multiple myeloma by Rocci, A, Hofmeister, C C, Geyer, S, Stiff, A, Gambella, M, Cascione, L, Guan, J, Benson, D M, Efebera, Y A, Talabere, T, Dirisala, V, Smith, E M, Omedè, P, Isaia, G, De Luca, L, Rossi, D, Gentili, S, Uccello, G, Consiglio, J, Ria, R, Benevolo, G, Bringhen, S, Callea, V, Weiss, B, Ferro, A, Magarotto, V, Alder, H, Byrd, J C, Boccadoro, M, Marcucci, G, Palumbo, A, Pichiorri, F

Get full text

Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’: [Ann Oncol 2021; 32(3): 309-322] by Dimopoulos, M.A., Moreau, P., Terpos, E., Mateos, M.V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., Goldschmidt, H., Facon, T., Einsele, H., Boccadoro, M., San-Miguel, J., Sonneveld, P., Mey, U.

Get full text

Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study) by Aapro, M., Ludwig, H., Bokemeyer, C., Gascón, P., Boccadoro, M., Denhaerynck, K., Krendyukov, A., Gorray, M., MacDonald, K., Abraham, I.

“…Risk models of chemotherapy-induced (CIN) and febrile neutropenia (FN) have to date focused on determinants measured at the start of chemotherapy. We extended…”
Get full text

Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis by Gay, F, Oliva, S, Petrucci, M T, Montefusco, V, Conticello, C, Musto, P, Catalano, L, Evangelista, A, Spada, S, Campbell, P, Ria, R, Salvini, M, Offidani, M, Carella, A M, Omedé, P, Liberati, A M, Troia, R, Cafro, A M, Malfitano, A, Falcone, A P, Caravita, T, Patriarca, F, Nagler, A, Spencer, A, Hajek, R, Palumbo, A, Boccadoro, M

“…In newly diagnosed myeloma patients, upfront autologous transplant (ASCT) prolongs progression-free survival 1 (PFS1) compared with chemotherapy plus…”
Get full text

Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma by Palumbo, A., Gay, F., Bringhen, S., Falcone, A., Pescosta, N., Callea, V., Caravita, T., Morabito, F., Magarotto, V., Ruggeri, M., Avonto, I., Musto, P., Cascavilla, N., Bruno, B., Boccadoro, M.

“…Bortezomib has shown significant activity in myeloma. In this multicenter trial, we assessed for the first time the combination of bortezomib, doxorubicin and…”
Get full text

Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma by Bringhen, S, D'Agostino, M, De Paoli, L, Montefusco, V, Liberati, A M, Galieni, P, Grammatico, S, Muccio, V E, Esma, F, De Angelis, C, Musto, P, Ballanti, S, Offidani, M, Petrucci, M T, Gaidano, G, Corradini, P, Palumbo, A, Sonneveld, P, Boccadoro, M

“…This multicentre, open-label phase 1/2 trial determined safety and efficacy of weekly carfilzomib plus cyclophosphamide–dexamethasone (wKCyd) in newly…”
Get full text